Who is sponsoring NCT00131430?

NCT00131430 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00131430?

Interventions in NCT00131430: taranabant.

What condition does NCT00131430 study?

NCT00131430 studies Obesity and Obesity-related Medical Conditions.

Is NCT00131430 still recruiting?

NCT00131430 is currently completed. Last updated 6 June 2016.

Last reviewed 2016-06-06 · How we verify

NCT00131430

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients

Completed Phase 2/Phase 3 Last updated 6 June 2016

What this trial tests

Phase 2/Phase 3 trial testing taranabant in Obesity and Obesity-related Medical Conditions in 500 participants. Completed in 1 May 2007.

Timeline

1 August 2005

Primary endpoint
1 May 2007

1 May 2007

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	500
Start date	1 August 2005
Primary completion	1 May 2007
Estimated completion	1 May 2007

Drugs / interventions tested

taranabant — full drug profile →

Conditions studied

Obesity and Obesity-related Medical Conditions — all drugs for Obesity and Obesity-related Medical Conditions →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Obesity and Obesity-related Medical Conditions. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

After 24 weeks, body weight, safety, and tolerability
Time frame: After 24 weeks

Sponsor's own description

A study to determine the safety and efficacy of an investigational drug in patients with obesity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The therapeutic potential of second and third generation CB<sub>1</sub>R antagonists.
Cinar R, Iyer MR, Kunos G. · · 2020 · cited 117× · PMID 31926199 · DOI 10.1016/j.pharmthera.2020.107477

Verify or expand the search:

Other recruiting trials for Obesity and Obesity-related Medical Conditions

Currently open trials in the same condition.

NCT06924177 — UTSW NORC Pilot Spinal Cord Injury Dietary Program · NA · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
NCT07213245 — Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) · NA · recruiting
NCT06768827 — New Mechanisms of Obesity · NA · recruiting
NCT06790225 — Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA) · NA · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00131430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 6 June 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00131430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing